All In Biotech

Drug Trial Radar · NCT00666666

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

A Phase II Study of AT101, to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Dec 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Jul 2009

Primary completion

May 2011

Study completion Jun 2012

Sponsor

Sponsor type
NIH
First posted
Apr 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial is studying how well giving gossypol together with androgen ablation therapy works in treating patients with newly diagnosed metastatic prostate cancer. Gossypol may stop the growth of tumor cells by blocking blood flow to the tumor. Androgens can cause the growth of prostate tumor cells. Luteinizing hormone-releasing hormone agonists and drugs, such as bicalutamide, may lessen the amount of androgens made by the body. Giving gossypol together with androgen ablation therapy may be an effective treatment for prostate cancer

Conditions

  • Adenocarcinoma of the Prostate
  • Stage IV Prostate Cancer

Interventions

  • AT-101Drug

    AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.

  • BicalutamideDrug

    Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.

  • LHRH agentOther

    An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 CyclesTime frame: 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

  • University of Michigan

    Ann Arbor, Michigan

  • Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.